{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:07:25Z","timestamp":1791040045191,"version":"4.1.0"},"reference-count":22,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Interleukin-2 (IL-2) and its receptor (IL-2R) play a major role in cellular immunity. The monoclonal antibodies basiliximab and daclizumab directed against the IL-2R subunit CD25 are widely used to prevent graft or host rejection after allogeneic tissue transplantation. Although these antibodies have been used for this purpose for many years, their common epitope within the CD25 protein is unknown. We screened a random phage display library to isolate peptides specifically binding to basiliximab. A striking amino acid sequence motif was enriched. This motif is homologous to the peptide ERIYHFV comprising amino acid positions 116 to 122 within the extracellular domain of CD25, suggesting that this is the basiliximab epitope. Basiliximab and daclizumab binding of selected phage was specific, as no binding was observed to isotype antibody controls. Phage binding could be inhibited by the cognate peptide. In cells expressing mutant CD25, binding of basiliximab was abolished when two or more amino acids of the suspected epitope were changed. In contrast, basiliximab binding remained unaffected in cells expressing CD25 versions with mutations outside this epitope. We therefore conclude that the (116)ERIYHFV(122) string within CD25 is the epitope recognized by basiliximab and daclizumab. This epitope overlaps with the interaction site of CD25 and IL-2, thus revealing the structural basis for the inhibition of IL-2R binding by this class of immunosuppressive antibodies. [Cancer Res 2007;67(8):3518\u201323]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-3919","type":"journal-article","created":{"date-parts":[[2007,4,17]],"date-time":"2007-04-17T14:39:26Z","timestamp":1176820766000},"page":"3518-3523","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Identification of Their Epitope Reveals the Structural Basis for the Mechanism of Action of the Immunosuppressive Antibodies Basiliximab and Daclizumab"],"prefix":"10.1158","volume":"67","author":[{"given":"Mascha","family":"Binder","sequence":"first","affiliation":[{"name":"1Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike-Nora","family":"Vo\u0308gtle","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Michelfelder","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Mu\u0308ller","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Illerhaus","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeth","family":"Sundararajan","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Mertelsmann","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Trepel","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology and"},{"name":"2Institute for Molecular Medicine and Cell Research, University of Freiburg Medical Center, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,4,17]]},"reference":[{"key":"2022061623200462300_B1","doi-asserted-by":"crossref","unstructured":"Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet\u20081997; 350: 1193\u20138.","DOI":"10.1016\/S0140-6736(97)09278-7"},{"key":"2022061623200462300_B2","doi-asserted-by":"crossref","unstructured":"Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood\u20081994; 84: 1320\u20137.","DOI":"10.1182\/blood.V84.4.1320.1320"},{"key":"2022061623200462300_B3","doi-asserted-by":"crossref","unstructured":"Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor \u03b1 chain antibody, for treatment of acute graft-versus-host disease. Blood\u20082000; 95: 83\u20139.","DOI":"10.1182\/blood.V95.1.83"},{"key":"2022061623200462300_B4","doi-asserted-by":"crossref","unstructured":"Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood\u20081993; 82: 1701\u201312.","DOI":"10.1182\/blood.V82.6.1701.1701"},{"key":"2022061623200462300_B5","doi-asserted-by":"crossref","unstructured":"Pankhurst T, Adu D. Antibodies in the prevention of renal allograft rejection. Expert Opin Biol Ther\u20082004; 4: 243\u201352.","DOI":"10.1517\/14712598.4.2.243"},{"key":"2022061623200462300_B6","doi-asserted-by":"crossref","unstructured":"Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its \u03b1, \u03b2, and \u03b3c receptors. Science\u20082005; 310: 1159\u201363.","DOI":"10.1126\/science.1117893"},{"key":"2022061623200462300_B7","doi-asserted-by":"crossref","unstructured":"Rickert M, Wang X, Boulanger MJ, Goriatcheva N, Garcia KC. The structure of interleukin-2 complexed with its \u03b1 receptor. Science\u20082005; 308: 1477\u201380.","DOI":"10.1126\/science.1109745"},{"key":"2022061623200462300_B8","doi-asserted-by":"crossref","unstructured":"Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. J Immunol\u20081981; 126: 1398\u2013403.","DOI":"10.4049\/jimmunol.126.4.1398"},{"key":"2022061623200462300_B9","doi-asserted-by":"crossref","unstructured":"Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol\u20082004; 56: 864\u20137.","DOI":"10.1002\/ana.20287"},{"key":"2022061623200462300_B10","doi-asserted-by":"crossref","unstructured":"Leonard WJ, Depper JM, Robb RJ, Waldmann TA, Greene WC. Characterization of the human receptor for T-cell growth factor. Proc Natl Acad Sci U S A\u20081983; 80: 6957\u201361.","DOI":"10.1073\/pnas.80.22.6957"},{"key":"2022061623200462300_B11","doi-asserted-by":"crossref","unstructured":"Soulillou JP. Immunosuppression through inhibition of interleukin-2\/interleukin-2 receptor interaction. Transplant Proc\u20081999; 31: 49\u201351S.","DOI":"10.1016\/S0041-1345(98)02082-X"},{"key":"2022061623200462300_B12","doi-asserted-by":"crossref","unstructured":"Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science\u20081990; 249: 386\u201390.","DOI":"10.1126\/science.1696028"},{"key":"2022061623200462300_B13","doi-asserted-by":"crossref","unstructured":"Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood\u20082006; 108: 1975\u20138.","DOI":"10.1182\/blood-2006-04-014639"},{"key":"2022061623200462300_B14","doi-asserted-by":"crossref","unstructured":"Riemer AB, Klinger M, Wagner S, et al. Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2\/neu. J Immunol\u20082004; 173: 394\u2013401.","DOI":"10.4049\/jimmunol.173.1.394"},{"key":"2022061623200462300_B15","doi-asserted-by":"crossref","unstructured":"Mintz PJ, Kim J, Do KA, et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol\u20082003; 21: 57\u201363.","DOI":"10.1038\/nbt774"},{"key":"2022061623200462300_B16","doi-asserted-by":"crossref","unstructured":"Vidal CI, Mintz PJ, Lu K, et al. An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene\u20082004; 23: 8859\u201367.","DOI":"10.1038\/sj.onc.1208082"},{"key":"2022061623200462300_B17","doi-asserted-by":"crossref","unstructured":"Muller OJ, Kaul F, Weitzman MD, et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol\u20082003; 21: 1040\u20136.","DOI":"10.1038\/nbt856"},{"key":"2022061623200462300_B18","doi-asserted-by":"crossref","unstructured":"Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood\u20082006; 107: 1070\u20137.","DOI":"10.1182\/blood-2005-04-1769"},{"key":"2022061623200462300_B19","doi-asserted-by":"crossref","unstructured":"Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst\u20082005; 97: 1663\u201370.","DOI":"10.1093\/jnci\/dji373"},{"key":"2022061623200462300_B20","doi-asserted-by":"crossref","unstructured":"Fellouse FA, Li B, Compaan DM, Peden AA, Hymowitz SG, Sidhu SS. Molecular recognition by a binary code. J Mol Biol\u20082005; 348: 1153\u201362.","DOI":"10.1016\/j.jmb.2005.03.041"},{"key":"2022061623200462300_B21","doi-asserted-by":"crossref","unstructured":"Villar HO, Kauvar LM. Amino acid preferences at protein binding sites. FEBS Lett\u20081994; 349: 125\u201330.","DOI":"10.1016\/0014-5793(94)00648-2"},{"key":"2022061623200462300_B22","doi-asserted-by":"crossref","unstructured":"Fellouse FA, Barthelemy PA, Kelley RF, Sidhu SS. Tyrosine plays a dominant functional role in the paratope of a synthetic antibody derived from a four amino acid code. J Mol Biol\u20082006; 357: 100\u201314.","DOI":"10.1016\/j.jmb.2005.11.092"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/8\/3518\/2582092\/3518.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/8\/3518\/2582092\/3518.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T10:11:24Z","timestamp":1683799884000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/8\/3518\/534990\/Identification-of-Their-Epitope-Reveals-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,15]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2007,4,17]]},"published-print":{"date-parts":[[2007,4,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-3919","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6496232","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6496232.v1","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22370012","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370012.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,15]]}}}